It is named after the German neurologist Alois Alzheimer, who was the first to describe the symptoms and typical brain changes in 1906. The disease is characterized by the slowly progressive loss of nerve cells and nerve cell contacts. Protein deposits (amyloid plaques and tau tangles) can be detected in the brains of those affected.
The clinical picture includes memory and orientation disorders, impaired thinking and judgment and changes in personality. These disorders can be of varying severity in those affected and make it increasingly difficult to go about everyday life normally. The first port of call for complaints is usually the general practitioner. If dementia is suspected, we often work together with specialists (neurology, psychiatry, geriatrics).
Eisai has many years of experience in the field of Alzheimer’s dementia and is working on the development of new drugs to treat the disease.
Information on Alzheimer’s dementia for patients and relatives can be found via the following links, for example:
Other treatment areas
Epilepsy is a chronic brain disease that affects people of all ages worldwide. It is one of the most common neurological diseases, affecting an estimated 50 million people worldwide1.
Specialist circles
Are you a specialist looking for information on our preparations?
For information on our preparations, please contact us directly, visit the homepage of the Swiss Agency for Therapeutic Products Swissmedic or our information platform for healthcare professionals at www.eisaipro.eu/en-ch.
